(d) if so, what was the pre-tax net profit, net worth the capital employed, the percentage of pre-tax profit to net worth an^ the sales turn over of formulations and bulk drugs of each company from 1979 to 1985; and

(e) what is the sales turn over of each Company in respect of Category I and II bulk drugs and formulations and what is the percentage to total sales turn over of formulations and bulk drugs of each company?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a), and (b) No, Sir. Government have not conducted any study of the profitability of 47 drugs companies referred to.

(c) To the extent information is available, the overall profitability norms fixed under Drugs (Price Con trol) Order, 1979 have not been exceeded.

(d) Does not arise.

(e) Details o" sale turnover category wise are not available.

Therapeutic group of Betamethasone

2317. SHRI (MOLANA) ASRARUL HAQ: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 778 given in the Rajya Sabha on the 25th March 1985 and state:

(a) whether it is a fact that NDPDC has recommended Betamethasone under the Therapeutic group of Dermatological products;

(b) if so, whether it is a fact that Glaxo has the monopoly of formulations based on this drug;

(c). whether it is also a fact that this company has a major sale of formulations based on this drug for Asthama indication and other indications;

(d) what is the rationale for covering the drug only for Dermatological indication when the same is used for other indications having high sales turn over: and

(e) what was the sales turn ever of the formulations based on this drug of Glaxo indication-wise during the last three years, year-wise and in which form each is being marketed?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEER ENDRA PATIL): (a) and (d) Yes, Sir. Some of the builk drugs listed in the priority list drawn up by the Medical Experts oi the National Drugs & Pharmaceuticals Develop ment Council have multiple uses. Every such bulk drug has been classi fied under a major therapeutic group. The consensus of the National Drugs & Pharmaceuticals Development Council was that all the formulations based on priority drugs will be under price control irrespective of the therapeutic group under which the bulk drug is placed.

(b) M/s. Glaxo Laboratories (India) Limited are the major pro ducers of the formulations based en Betamethasone.

(c) and (e) The names of the for mulations based on Betamethasone and their sales turn over during the last three years have already been furnished in reply to Rajya Sabha Unstarred Question No. 778 answered on 25-3-1985. Details of sales of formulations by the company indi cation-wise are not monitored.

Fixation of price of Minaphillin

2318. SHRI (MOLANA) ASRARUL HAQ. Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) when and what price was fixed for Minaphillin Tablets and injections and what price of Theophil-lin and Etofyllin was taken in account while working the formulation price;

(b) whether it is a fact that these products are manufactured by two companies and marketed by one;

(c)| what is the relation of Board of Directors of each company with the other, the name and other details of each Director;

(d) whether it is a fact that these companies purchased bulk drugs at cheaper prices;

(e) if so, whether the purchase invoice was verified;

(f) what was the quantity of these two drugs procured by each company during the last three years, year-wise, price per kg. and source of procurement;

(g) whether it is a fact that this company is overcharging the price °* Orogyl Tablets and Suspensions; and

(h) what is the market price of aidazole and at what price of these formulations are fixed?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) A Statement giving the information as asked for is attached.

(b) Minaphillin Injection is manufactured and marketed by M/s. Fair-deal Corporation whereas Minaphillin Tablets are manufactured (by M/s. Akhil Pharma and marketed by M|s. Fairdeal Corporation.

(c) The position is being ascertained.

(d). and (e) In fixing the price of the formulations the average landed cost of imports has been allowed.

(f) Details are being collected and would be laid on the Table of the Raiya Sabha.

(g) and (h) The price of Metro nidazole was reduced from Rs. 497.98 to Rs. 363 per kg. Based on this reduction in the price of the bulk drug, the formulation prices were also reduced. M/s. Fair-deal Corporation has further submit ted a representation against the re duction in price of Metronidazole and formulations sold under the brand name Orogyl. The represen tations are in an advance stage of consideration.

Statement

Sl. No.	Name of the formulation	Pack size	Retail price as approved by the Govt.	Date of approval	Rate of bulk drug taken into considera-tion
1	Minaphillin Inj.	5 Amp ×2 ml.	5.49	16-3-75	Hydroxy Ethyl Theo-phyline Rs. 332 per Kg.
2	Minaphillin Inj.	50 Amp ×2 ml.	52.89	23-3-85	Theophylline Rs. 198 per Kg. Hydroxy Ethyl Theophylline Rs. 337.29 per Kg.
3	Minaphillin Tabs.	10's	1.32	13-2-85	Do.
		500's	38.93	13-2-85	Do.
		1000's	73.31	13-2-85	Do.